SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rivero SJ, Diaz-Jouanen E, Alarcon-Segovia D. Lymphopenia in systemic lupus erythematosus: clinical, diagnostic, and prognostic significance. Arthritis Rheum 1978; 21: 295305.
  • 2
    Ward MM, Studenski S. Age associated clinical manifestations of systemic lupus erythematosus: a multivariate regression analysis. J Rheumatol 1990; 17: 47681.
  • 3
    Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Cohen PL, et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002; 11: 1617.
  • 4
    Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics.” Medicine (Baltimore) 2004; 83: 117.
  • 5
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 6
    Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 110718.
  • 7
    Liang MH, Fortin PR, Isenberg DA, Snaith L. Quantitative clinical assessment of disease activity in systemic lupus erythematosus: progress report and research agenda. Rheumatol Int 1991; 11: 1336.
  • 8
    Utsinger PD. Relationship of lymphocytotoxic antibodies to lymphopenia and parameters of disease activity in systemic lupus erythematosus. J Rheumatol 1976; 3: 17585.
  • 9
    Mirzayan MJ, Schmidt RE, Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford) 2000; 39: 13169.
  • 10
    Lenert P, Lenert G, Senecal JL. CD4-reactive antibodies in systemic lupus erythematosus. Hum Immunol 1996; 49: 3848.
  • 11
    Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, et al, and the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum 1998; 41: 116172.
  • 12
    Alarcon GS, McGwin G Jr, Uribe A, Friedman AW, Roseman JM, Fessler BJ, et al, and the LUMINA Study Group. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum 2004; 51: 46574.
  • 13
    Vila LM, Alarcon GS, McGwin G Jr, Friedman AW, Baethge BA, Bastian HM, et al, and the LUMINA Study Group. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology (Oxford) 2004; 43: 35863.
  • 14
    Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 30913.
  • 15
    Drenkard C, Villa AR, Reyes E, Abello M, Alarcon-Segovia D. Vasculitis in systemic lupus erythematosus. Lupus 1997; 6: 23542.
  • 16
    Wenzel J, Gerdsen R, Uerlich M, Bauer R, Tueting T, Bieber T. Lymphocytopenia in lupus erythematosus: close in vivo association to autoantibodies targeting nuclear antigens. Br J Dermatol 2004; 150: 9948.
  • 17
    Harley JB, Sestak AL, Willis LG, Fu SM, Hansen JA, Reichlin M. A model for disease heterogeneity in systemic lupus erythematosus: relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum 1989; 32: 82636.
  • 18
    Shoenfeld Y, Zamir R, Joshua H, Lavie G, Pinkhas J. Human monoclonal anti-DNA antibodies react as lymphocytotoxic antibodies. Eur J Immunol 1985; 15: 10248.
  • 19
    Alarcon GS, McGwin G Jr, Bartolucci AA, Roseman J, Lisse J, Fessler BJ, et al, and the LUMINA Study Group. Lupus in Minority Populations, Nature versus Nurture. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001; 44: 2797806.
  • 20
    Alarcon GS, McGwin G Jr, Bastian HM, Roseman J, Lisse J, Fessler BJ, et al, and the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. VIII. Predictors of early mortality in the LUMINA cohort. Arthritis Rheum 2001; 45: 191202.
  • 21
    Halberg P, Alsbjorn B, Balslev JT, Lorenzen I, Gerstoft J, Ullman S, et al. Systemic lupus erythematosus: follow-up study of 148 patients. II. Predictive factors of importance for course and outcome. Clin Rheumatol 1987; 6: 226.
  • 22
    Silvestris F, Grinello D, Tucci M, Cafforio P, Dammacco F. Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus 2003; 12: 814.
  • 23
    Kaneko H, Saito K, Hashimoto H, Yagita H, Okumura K, Azuma M. Preferential elimination of CD28+ T cells in systemic lupus erythematosus (SLE) and the relation with activation-induced apoptosis. Clin Exp Immunol 1996; 106: 21829.
  • 24
    Nakabayashi K, Arimura Y, Yoshida M, Nagasawa T. Anti-T cell antibodies in primary glomerulonephritis. Clin Nephrol 1985; 23: 7480.
  • 25
    Sun KH, Tang SJ, Lin ML, Wang YS, Sun GH, Liu WT. Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatology (Oxford) 2001; 40: 7506.
  • 26
    Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al, and the European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299308.
  • 27
    Edwards CJ, Lian TY, Badsha H, Teh CL, Arden N, Chng HH. Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus 2003; 12: 6726.
  • 28
    Scheinberg MA, Cathcart ES. B cell and T cell lymphopenia in systemic lupus erythematosus. Cell Immunol 1974; 12: 30914.
  • 29
    Wouters CH, Diegenant C, Ceuppens JL, Degreef H, Stevens EA. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship. Br J Dermatol 2004; 150: 693700.
  • 30
    Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165: 59709.
  • 31
    Hutin P, Lamour A, Pennec YL, Soubrane C, Dien G, Khayat D, et al. Cell-free Fc-gamma receptor III in sera from patients with systemic lupus erythematosus: correlation with clinical and biological features. Int Arch Allergy Immunol 1994; 103: 237.
  • 32
    Robak E, Smolewski P, Wozniacka A, Sysa-Jedrzejowska A, Robak T. Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus. Mediators Inflamm 2004; 13: 17180.
  • 33
    Nossent JC, Swaak AJ. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med 1991; 80: 60512.